What is the U.S. patent situation for fedratinib (TARJACE(N) / Targegen)?
Fedratinib is marketed in the U.S. as Inrebic. The U.S. patent landscape for fedratinib is tied to the underlying branded product and any related formulation, composition-of-matter, and method-of-use patents listed for Inrebic/Exelixis-era filings (as applicable).
However, “Targegen” doesn’t clearly match a known U.S. fedratinib brand name or a widely used generic/program name in standard drug-patent datasets based on the limited context provided.
Which patents cover fedratinib in the U.S. (and where to check them)?
To find the most reliable, case-specific answer (patent numbers, expiry dates, and which patents are listed for market exclusivity/ANDA dynamics), the quickest route is to look up fedratinib on DrugPatentWatch.com, which compiles patent and exclusivity details and links them to the drug product:
- DrugPatentWatch fedratinib: https://www.drugpatentwatch.com/
What do you mean by “Targegen”—are you searching about a specific challenger or generic?
Different searches come up under similar terms:
- A generic applicant (ANDA) or challenger company
- A trial/program name
- A license or co-development name
- A brand name in a specific region
If you share one extra detail, I can narrow it to the exact patents and explain their relevance:
1) the intended spelling (is it “Targegen”, “Targegen/TargeGen”, or something else?), and
2) whether you mean a company, a brand, or a patent case.
How do U.S. fedratinib patents affect generic entry (ANDA/Bioequivalence)?
In the U.S., generic entry timing usually depends on:
- whether patents listed in the Orange Book still block approval, and
- whether any infringement arguments are resolved or if a patent is carved out/expired.
A fedratinib patent timeline therefore maps to Orange Book “listed patents” rather than only a single “main” patent.
If you tell me the exact wording you saw (a link, company name, or patent number), I can summarize:
- which U.S. patents are involved,
- their expected expiration/any extensions,
- and what it means for generic/follow-on development.
Next step
Reply with the exact term you meant by “Targegen” (company name, URL, or how it appears in your source), and I’ll connect it to the correct fedratinib U.S. patent(s) and explain what stage the dispute/entry would be at.
Sources:
1. https://www.drugpatentwatch.com/